Hemophagocytic Lymphohistiocytoses Clinical Trial
Official title:
Clinical Study on the Efficacy and Safety of Carrimycin Tablets in Hemophagocytic Lymphohistiocytosis Patients With Carbapenem-resistant Infections
This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
Hemophagocytic lymphohistiocytosis (HLH) is a critical condition characterized by the undue activation of cytotoxic T lymphocytes, natural killer cells, and macrophages, resulting in excessive secretion of infammatory cytokines. Infection is an important trigger for HLH. This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05491304 -
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
|
Phase 4 | |
| Completed |
NCT05531721 -
HLH Patients - a Retrospective Study
|
||
| Not yet recruiting |
NCT05600959 -
Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
|
||
| Completed |
NCT03546101 -
Early Detection of Epstein-Barr Virus Related Disease.
|
||
| Recruiting |
NCT05898477 -
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
|
||
| Recruiting |
NCT05882175 -
Prospective Validation of the OHI Index
|
||
| Recruiting |
NCT05146336 -
CytOSorb TreatMent Of Critically Ill PatientS Registry
|
||
| Not yet recruiting |
NCT04902807 -
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
|
||
| Terminated |
NCT03985423 -
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
|
Phase 2/Phase 3 | |
| Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05677178 -
Response Prediction in EBV-HLH Using Metabonomics Analysis
|
||
| Recruiting |
NCT03117010 -
Prospective Cohort for Adult Hemophagocytosis
|
||
| Not yet recruiting |
NCT06160791 -
Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
|
Phase 2 | |
| Recruiting |
NCT05236764 -
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
|
N/A | |
| Recruiting |
NCT05277272 -
INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
|
||
| Completed |
NCT06047210 -
Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
|